Persistent disparities in diabetes medication receipt by socio‐economic disadvantage in Australia

BACKGROUND: It is unknown how use of newer glucose‐lowering drugs (GLDs) has changed in Australia following the publication of clinical trials demonstrating definitive clinical advantages for glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) and sodium‐glucose co‐transporter 2 inhibitors (SGLT2i...

Descripción completa

Detalles Bibliográficos
Autores principales: Morton, Jedidiah I., Ilomӓki, Jenni, Magliano, Dianna J., Shaw, Jonathan E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Research: Epidemiology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9545050/
https://www.ncbi.nlm.nih.gov/pubmed/35694847
http://dx.doi.org/10.1111/dme.14898

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9545050/
https://www.ncbi.nlm.nih.gov/pubmed/35694847
http://dx.doi.org/10.1111/dme.14898

Ejemplares similares